PerkinElmer, Inc. (NYSE:PKI) Shares Sold by Axa S.A.

Posted by Defense World Staff on Mar 1st, 2023

Axa S.A. trimmed its holdings in shares of PerkinElmer, Inc. (NYSE:PKI – Get Rating) by 38.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,670 shares of the medical research company’s stock after selling 4,748 shares during the period. Axa S.A.’s holdings in PerkinElmer were worth $923,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of PKI. Price T Rowe Associates Inc. MD lifted its stake in PerkinElmer by 0.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 15,014,808 shares of the medical research company’s stock valued at $2,135,406,000 after buying an additional 68,732 shares in the last quarter. State Street Corp grew its position in PerkinElmer by 0.3% in the second quarter. State Street Corp now owns 5,171,403 shares of the medical research company’s stock worth $735,477,000 after buying an additional 14,692 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in PerkinElmer by 10.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,624,231 shares of the medical research company’s stock worth $657,660,000 after purchasing an additional 448,080 shares during the period. Invesco Ltd. boosted its stake in shares of PerkinElmer by 1.9% during the 1st quarter. Invesco Ltd. now owns 1,180,717 shares of the medical research company’s stock valued at $205,986,000 after buying an additional 22,532 shares during the period. Finally, Robeco Schweiz AG lifted its stake in shares of PerkinElmer by 2.9% in the 1st quarter. Robeco Schweiz AG now owns 1,060,731 shares of the medical research company’s stock valued at $185,055,000 after purchasing an additional 30,227 shares during the last quarter. 85.22% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other PerkinElmer news, insider Tajinder S. Vohra sold 1,663 shares of the business’s stock in a transaction that occurred on Tuesday, December 20th. The shares were sold at an average price of $138.85, for a total transaction of $230,907.55. Following the completion of the transaction, the insider now directly owns 17,205 shares in the company, valued at $2,388,914.25. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.52% of the stock is currently owned by corporate insiders.

PerkinElmer Stock Up 1.1 %

Shares of NYSE:PKI opened at $124.57 on Wednesday. The firm has a market cap of $15.72 billion, a price-to-earnings ratio of 27.20, a PEG ratio of 0.53 and a beta of 1.09. PerkinElmer, Inc. has a 12-month low of $113.46 and a 12-month high of $184.75. The company has a current ratio of 2.11, a quick ratio of 1.85 and a debt-to-equity ratio of 0.53. The stock’s 50-day moving average price is $136.08 and its two-hundred day moving average price is $134.93.

PerkinElmer (NYSE:PKI – Get Rating) last announced its quarterly earnings results on Tuesday, February 14th. The medical research company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.66 by $0.04. The company had revenue of $741.20 million during the quarter, compared to analyst estimates of $1.07 billion. PerkinElmer had a return on equity of 13.94% and a net margin of 14.69%. The firm’s quarterly revenue was down 27.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.56 EPS. On average, research analysts forecast that PerkinElmer, Inc. will post 5.07 EPS for the current year.

PerkinElmer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 12th. Shareholders of record on Friday, April 21st will be issued a dividend of $0.07 per share. The ex-dividend date is Thursday, April 20th. This represents a $0.28 annualized dividend and a yield of 0.22%. PerkinElmer’s dividend payout ratio is presently 6.11%.

Analyst Ratings Changes

A number of research firms recently weighed in on PKI. Cowen raised shares of PerkinElmer from a “market perform” rating to an “outperform” rating and set a $164.00 target price on the stock in a research note on Tuesday, December 6th. StockNews.com lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a research report on Thursday, November 10th. TheStreet upgraded shares of PerkinElmer from a “c+” rating to a “b” rating in a research report on Tuesday, February 14th. Barclays decreased their price target on shares of PerkinElmer from $145.00 to $140.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 24th. Finally, Cowen upgraded shares of PerkinElmer from a “market perform” rating to an “outperform” rating and reduced their target price for the stock from $192.00 to $164.00 in a research note on Tuesday, December 6th. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $166.30.

PerkinElmer Company Profile

(Get Rating)

PerkinElmer, Inc engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments.